AdvanCell
Develops lead-212 targeted alpha therapies to treat cancer
$315MSeries D
Role not disclosedLoading investors…
Activity from announced rounds
Develops lead-212 targeted alpha therapies to treat cancer
Develops AI-designed CAR T therapies for solid tumors using spatial biology
Pitching Time BioVentures? Send the deck from a free RoundOS data room and see which pages they read.
Create a free room